Syros Pharmaceuticals, Inc.(SYRS)

Description: Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

---

Keywords: Cancer Biopharmaceutical Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Acute Leukemia Immune Mediated Diseases Refractory Acute Myeloid Leukemia

---

Home Page: www.syros.com

SYRS Technical Analysis

35 CambridgePark Drive
Cambridge, MA 02140
United States
Phone: 617 744 1340

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)